EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Non-Canonical p75HER2 Signaling Pathway Underlying Trastuzumab Action and Resistance in Breast Cancer

Babak Nami, Zhixiang Wang iD

Cells · 2024

DOI: 10.3390/cells13171452 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Babak Nami und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada. Hauptthemen laut MEDLINE: Trastuzumab, Breast Neoplasms, Signal Transduction, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institute of Health Research, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Overexpression of HER2 occurs in 25% of breast cancer. Targeting HER2 has proven to be an effective therapeutic strategy for HER2-positive breast cancer. While trastuzumab is the most commonly used HER2 targeting agent, which has significantly improved outcomes, the overall response rate is low. To develop novel therapies to boost trastuzumab efficacy, it is critical to identify the mechanisms underlying trastuzumab action and resistance. We recently showed that the inhibition of breast cancer cell growth by trastuzumab is not through the inhibition of HER2 canonical signaling. Here we report the identification of a novel non-canonical HER2 signaling pathway and its interference by trastuzumab. We showed that HER2 signaled through a non-canonical pathway, regulated intramembrane proteolysis (RIP). In this pathway, HER2 is first cleaved by metalloprotease ADAM10 to produce an extracellular domain (ECD) that is released and the p95HER2 that contains the transmembrane domain (TM) and intracellular domain (ICD). p95HER2, if further cleaved by an intramembrane protease, γ-secretase, produced a soluble ICD p75HER2 with nuclear localization signal (NLS). p75HER2 is phosphorylated and translocated to the nucleus. Nuclear p75HER2 promotes cell proliferation. Trastuzumab targets this non-canonical HER2 pathway via inhibition of the proteolytic cleavage of HER2 by both ADAM10 and γ-secretase. However, p75HER2 pathway also confers resistance to trastuzumab once aberrantly activated. Combination of trastuzumab with ADAM10 and γ-secretase inhibitors completely blocks p75HER2 production in both BT474 and SKBR3 cells. We concluded that HER2 signals through the RIP signaling pathway that promotes cell proliferation and is targeted by trastuzumab. The aberrant HER2 RIP signaling confers resistance to trastuzumab that could be overcome by the application of inhibitors to ADAM10 and γ-secretase.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrastuzumabBreast NeoplasmsSignal TransductionDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesHumansFemaleCell Line, TumorAmyloid Precursor Protein SecretasesADAM10 ProteinCell ProliferationProteolysisMembrane Proteins

Stichwörter der Autor:innen

ADAM10HER2breast cancerdrug resistancep75HER2regulated intramembrane proteolysissignaling pathwaystrastuzumabγ-secretase

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesAmyloid Precursor Protein SecretasesADAM10 ProteinMembrane ProteinsERBB2 protein, humanADAM10 protein, human

Autor:innen und Institutionen

  • Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada.

ORCID-Profile: Zhixiang Wang

Förderung

  • Canadian Institute of Health Research
  • Canadian Institutes of Health Research

Zitieren

APA

Nami, B., & Wang, Z. (2024). A Non-Canonical p75HER2 Signaling Pathway Underlying Trastuzumab Action and Resistance in Breast Cancer. Cells. https://doi.org/10.3390/cells13171452

Vancouver

Nami B, Wang Z. A Non-Canonical p75HER2 Signaling Pathway Underlying Trastuzumab Action and Resistance in Breast Cancer. Cells. 2024. doi:10.3390/cells13171452

BibTeX
@article{Nami2024,
  author = {Nami, Babak and Wang, Zhixiang},
  title = {A Non-Canonical p75HER2 Signaling Pathway Underlying Trastuzumab Action and Resistance in Breast Cancer},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13171452}
}
Kostenlos starten →